Key result
Several prognostic and predictive biomarkers for cardiovascular risk in chronic kidney disease have been developed, but few are in clinical use due to heterogeneous results and lack of validation.
Why the study?
Despite providing pathophysiological information beyond proteinuria and eGFR, few CV risk biomarkers in CKD are used clinically due to heterogeneous results and lack of validation.
This review highlights the potential of prognostic and predictive biomarkers to improve cardiovascular risk stratification in CKD patients, while emphasizing the need for better validation to enable clinical adoption.
No takes yet. Share an insight, caveat, or question.
May refine CV risk stratification in CKD; leaves open clinical adoption pending prospective validation.
Provenzano et al. (2020) conducted a review in Chronic Kidney Disease. Prognostic and predictive biomarkers was evaluated. Several prognostic and predictive biomarkers for cardiovascular risk in chronic kidney disease have been developed, but few are in clinical use due to heterogeneous results and lack of validation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: